Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HydraFlex is a non-specific brand name associated with several health-related products, most notably a line of joint health supplements and medical devices. In the context of joint health, HydraFlex typically refers to formulations containing **sodium hyaluronate** (hyaluronic acid), often combined with other chondroprotective agents such as **glucosamine**, **chondroitin sulfate**, and **methylsulfonylmethane (MSM)**. These products are designed to support joint function by replenishing synovial fluid viscosity, enhancing lubrication, and providing structural precursors for cartilage repair. The mechanism of action primarily involves the binding of hyaluronic acid to the **CD44 receptor**, which modulates inflammatory responses and stimulates endogenous hyaluronan production. Additionally, the name HydraFlex is used for medical devices, including a proprietary flexible intravenous (IV) solution container system developed by **B. Braun** and a line of contact lenses produced by **CooperVision**.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on HydraFlex.